Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Lessened by WCM Investment Management LLC

WCM Investment Management LLC lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 300,045 shares of the biopharmaceutical company's stock after selling 10,784 shares during the quarter. WCM Investment Management LLC owned approximately 0.24% of Halozyme Therapeutics worth $17,094,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in HALO. Nations Financial Group Inc. IA ADV increased its position in Halozyme Therapeutics by 6.3% during the third quarter. Nations Financial Group Inc. IA ADV now owns 13,734 shares of the biopharmaceutical company's stock worth $786,000 after buying an additional 815 shares in the last quarter. Assetmark Inc. lifted its holdings in Halozyme Therapeutics by 9.9% in the 3rd quarter. Assetmark Inc. now owns 93,159 shares of the biopharmaceutical company's stock worth $5,332,000 after purchasing an additional 8,385 shares during the last quarter. Verdence Capital Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock worth $757,000 after purchasing an additional 252 shares in the last quarter. Portside Wealth Group LLC raised its position in shares of Halozyme Therapeutics by 132.1% during the third quarter. Portside Wealth Group LLC now owns 9,123 shares of the biopharmaceutical company's stock worth $522,000 after acquiring an additional 5,192 shares during the last quarter. Finally, Hanseatic Management Services Inc. bought a new stake in shares of Halozyme Therapeutics during the third quarter worth $581,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 2.4 %

NASDAQ HALO traded down $1.48 on Tuesday, hitting $59.61. The company's stock had a trading volume of 1,510,776 shares, compared to its average volume of 1,289,879. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company's 50-day moving average is $56.56 and its 200 day moving average is $53.03. The firm has a market cap of $7.58 billion, a PE ratio of 20.23, a PEG ratio of 0.56 and a beta of 1.29.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 9,881 shares of the firm's stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the sale, the director now owns 69,874 shares of the company's stock, valued at $4,031,729.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $9,254,244.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 79,881 shares of company stock worth $4,612,634. Company insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HALO. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and boosted their target price for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Benchmark reissued a "buy" rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. TD Cowen raised their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. The Goldman Sachs Group raised their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a "neutral" rating in a report on Monday, July 22nd. Finally, HC Wainwright raised their price target on Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.